Assessment of a new point-of-care system for detection of prostate specific antigen

BMC Urology

Volumn 16, Issue 1, 2016, Pages

  Rausch, Steffen ^a   Hennenlotter, Joerg ^a   Wiesenreiter, Josef ^a   Hohneder, Andrea ^a   Heinkele, Julian ^a   Schwentner, Christian ^a   Stenzl, Arnulf ^a   Todenhöfer, Tilman ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Point of care; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PREDICTIVE VALUE; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; AREA UNDER THE CURVE; BLOOD; EARLY CANCER DIAGNOSIS; MIDDLE AGED; POINT OF CARE SYSTEM; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; STATISTICAL MODEL;

AGED; AREA UNDER CURVE; COHORT STUDIES; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; LINEAR MODELS; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; POINT-OF-CARE TESTING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84955506575     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/s12894-016-0119-9     Document Type: Article

References (21)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17(2):159-63.
2. Gui-Zhong L, Libo M, Guanglin H, Jianwei W. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol. 2011;43(2):295-301.
3. Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM, et al. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology. 2005;65(2):300-5.
4. Stancik I, Luftenegger W, Klimpfinger M, Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol. 2004;46(6):760-4.
5. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004;58(4):382-90.
6. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999;53(3):473-80.
7. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-9.
8. Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R, et al. Prostate cancer patients' support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology. 2003;12(8):769-83.
9. Brouwer N, van Pelt J. Validation and evaluation of eight commercially available point of care CRP methods. Clin Chim Acta. 2015;439:195-201.
10. Syal K. Point of care testing for measurement of white blood cell count and C-reactive protein levels in blood. Clin Chim Acta. 2014;437:218.
11. Knaebel J, Irvin BR, Xie CZ. Accuracy and clinical utility of a point-of-care HbA1c testing device. Postgrad Med. 2013;125(3):91-8.
12. Sanchez-Mora C, S Rodríguez-Oliva M, Fernández-Riejos P, Mateo J, Polo-Padillo J, Goberna R. Evaluation of two HbA1c point-of-care analyzers. Clin Chem Lab Med. 2011;49(4):653-7.
13. Karim O, Rao A, Emberton M, Cochrane D, Partridge M, Edwards P, et al. Point-of-care PSA testing: an evaluation of PSAwatch. Prostate Cancer Prostatic Dis. 2007;10(3):270-3.
14. Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol. 2008;129(6):952-8.
15. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467-79.
16. Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol. 2005;173(3):777-80.
17. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.
18. Wilkinson S, Warren K, Ramsden A, Matthews A, Chodak G. Do "rapid" PSA assays reduce anxiety and stress of prostate cancer patients undergoing regular review? A prospective evaluation. Urology. 2008;71(4):567-72.
19. Miano R, Mele GO, Germani S, Bove P, Sansalone S, Pugliese PF, et al. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test. Prostate Cancer Prostatic Dis. 2005;8(3):219-23.
20. Oh SW, Kim YM, Kim HJ, Kim SJ, Cho JS, Choi EY. Point-of-care fluorescence immunoassay for prostate specific antigen. Clin Chim Acta. 2009;406(1-2):18-22.
21. Oberpenning F, Hetzel S, Weining C, Brandt B, De Angelis G, Heinecke A, et al. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol. 2003;43(5):478-84.